Case Studies
Client Situation
A midsize biopharma client wanted to create a rep-centric tool to help them understand their targets and map against current performance and gaps, identify changes in market scenario, manage schedules, prioritize targets and deliver contextual content
Trinity’s Role
Trinity developed a comprehensive field force tool to track target treatment paradigms, analyze market drivers and identify Next Best Actions (NBAs)
Integrated tightly with rep calendars to provide triggers with insights and recommendations contextual to rep schedules
Leveraged multiple data…
Read Now
Webinars
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the impacts for pharma manufacturers.
Register for this webinar for a deeper dive into a few trends in the white paper. Join experts from our Evidence,…
Watch Now
Case Studies
Client Situation
A large biopharma customer wanted to optimize their digital channel strategy and outreach to most effectively engage with HCPs
Trinity’s Role
Trinity developed an AI solution that predicts the next best digital channel, content and cadence to engage with individual HCPs
Although originally created for one brand, the technology and AI model was crafted so that it could be scaled and easily configured to add different criteria and datasets
After success with the initial brand, Trinity expanded the…
Read Now
White Papers
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased implementation of cost-effectiveness policies and the emergence of the consequences of these pricing controls and cost-effectiveness measures, including the Inflation Reduction Act (IRA) and Germany’s…
Read Now
Blog
Published February 26, 2024
Executive Summary
Multiple cost-containment reforms, such as the introduction of a 20% rebate on brand-brand combinations and a temporary increase in the mandatory rebate on drugs to 12%, were implemented under Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz) in 2023. The evaluation report of these strategies showed that the actual savings for the year fell short of the proposed target (25% deficit, €1.4 Bn vs. target of €1.9 Bn) for all such reforms except 30% higher savings…
Read Now
Blog
Published February 15, 2024
2023 was a busy year for cell and gene therapies (C>). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications where competition is better established (e.g., hemophilia A and B).
Towards the end of the year, the FDA approved not one, but two sickle cell gene therapies on the same day, creating instant competition between them. One of these…
Read Now
Webinars
Available On Demand
Across life sciences commercialization organizations, attention is shifting to best practices in strengthening the connection between healthcare professionals (HCPs) and patients. Join Susheel Sukhtankar, Partner and Head of Commercial Analytics at Trinity Life Sciences, as he hosts a dynamic discussion on the nuances of omnichannel orchestration with panelists Jerry Luciano, Vice President of Omnichannel Marketing at TGaS Advisors, a Division of Trinity Life Sciences, and Anushank Anand, Director of Omnichannel Analytics in Trinity’s Commercial Analytics practice.
Key Webinar Topics
Linking…
Watch Now
Webinars
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, this webinar is a must-watch.
Join us for an informative webinar as our experts dive into Trinity Life Sciences’ latest white paper, the Trinity Annual Drug Index—an evaluation of commercial performance over three years of 58 novel drugs approved in 2020.
Hear from Blair Miller, Krista Perry, Hanson Koota and Smit Mahida from our Strategic Advisory practice as they discuss the impacts of COVID on the 2020 launch…
Watch Now
Blog
Published January 29, 2024
Introduction
In the summer of 2023, many oncologists and cancer patients faced an impossible choice. Amidst many challenging treatment decisions, they had to determine how to proceed without two mainstays among oncology therapeutics: cisplatin and carboplatin. While it can sometimes be expected that there may be delays for the newest and most innovative treatments to reach patients, both cisplatin and carboplatin have been available for over twenty years, are used frequently in oncology regimens and are not considered particularly expensive.…
Read Now
Blog
Published January 12, 2024
Introduction
The Trinity Life Sciences’ team recently attended the 65th ASH Annual Meeting and Exposition from December 9-12, 2023, in San Diego, California. The conference brought together physicians, scientists and industry experts to share and collaborate on advances in understanding and treating blood cancers and blood disorders. Below are a few of the key insights that the Trinity team observed during the conference:
Advances in CAR-T Therapy: Expansion into New Targets and Therapeutic Areas
Numerous groups across the industry are…
Read Now
